These results suggest that the mechanism of action of FK506 involves a partial correction of endoglin and ALK1 haplosufficiency, and may therefore be an interesting drug for use in patients with HHT. The gene discussed is ACVRL1; the disease is hereditary hemorrhagic telangiectasia.